PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
Portfolio Pulse from
PharmAla Biotech Holdings Inc. has partnered with Merhavim Mental Health Centre in Israel to supply materials for a clinical trial on MDMA-assisted psychotherapy for PTSD. In return, PharmAla will receive a full data license for regulatory and commercial use.
January 20, 2025 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PharmAla Biotech Holdings Inc. has entered a partnership with Merhavim Mental Health Centre to supply MDMA for a clinical trial, gaining a full data license for regulatory and commercial purposes.
The partnership allows PharmAla to gain valuable clinical data for regulatory and commercial use, potentially enhancing its product offerings and market position. This is likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90